Drug Search Results
More Filters [+]

LY-3023703

Alternative Names: ly-3023703, ly3023703, ly 3023703
Latest Update: 2018-12-14
Latest Update Note: Clinical Trial Update

Product Description

a novel microsomal prostaglandin e synthase 1 inhibitor (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26351780/)

Mechanisms of Action: MPGES Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for LY-3023703

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Acute Pain

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

I6H-MC-MCBB

P1

Completed

Healthy Volunteers

2013-12-01

I6H-MC-MCBC

P2

Completed

Acute Pain

2013-10-01

I6H-MC-MCBD

P1

Terminated

Healthy Volunteers

2013-10-01

I6H-MC-MCBA

P1

Completed

Healthy Volunteers

2012-09-01

Recent News Events

Date

Type

Title